Maveropepimut-S (MVP-S) and Low-Dose CPA in Patients With Platinum-Resistant Ovarian Cancer

Key Inclusion Criteria:

* Stage III or IV epithelial ovarian, fallopian tube, or primary peritoneal cancer, histologically diagnosed high-grade serous
* Platinum-resistant disease (relapsing within 3-6 months after completion of initial platinum-based treatment). Patients progressing at any time on or after ≥ 2nd platinum-based therapy are eligible.
* Received ≤ 4 prior lines of anti-cancer therapy for ovarian cancer, including at least one platinum-based therapy
* Evidence of progressive disease
* Measurable disease (RECIST v1.1) with at least one non-target lesion accessible by image-guided biopsy. No single lesion may be larger than 4 cm in diameter.
* Completed pre-treatment tumor biopsy and willing to undergo on-treatment tumor biopsy
* ECOG 0-1
* Live expectancy ≥ 6 months
* Meet protocol-specified laboratory requirements

Key Exclusion Criteria:

* Concurrent chemotherapy drugs, anti-cancer therapy or anti-neoplastic hormonal therapy, or radiotherapy
* Prior receipt of survivin-based vaccines/therapy, immune checkpoint inhibitors, IDO inhibitor, or cell-based therapy
* Non-epithelial tumor origin of the ovary, fallopian tube, or peritoneum
* Clinical ascites
* Concurrent second malignancy other than basal or squamous cell skin cancer, cervical carcinoma in situ, or Stage I or II caner in complete remission
* GI condition that might limit absorption of oral agents
* Recent history of thyroiditis
* History of autoimmune disease requiring treatment within the last two years (except paraneoplastic syndrome, vitiligo, or diabetes)
* History of bowel obstruction related to the disease
* Presence of a serious acute infection or chronic infection
* Uncontrolled concurrent illness or history of significant cardiac or pulmonary disfunction
* Myocardial infarction or cerebrovascular event within past 6 months
* Known central nervous system (CNS) or leptomeningeal metastasis (brain metastases)
* Clinically significant illness or major surgery within past 28 days or anticipated need for major surgery during study treatment
* Ongoing treatment with steroid therapy or other immunosuppressive
* Receipt of live attenuated vaccines
* Edema or lymphedema in the lower limbs \> grade 2
* Acute or chronic skin and/or microvascular disorders